Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.20 USD
7.60 M USD
0.00 USD
51.61 M
About BridgeBio Oncology Therapeutics, Inc.
Sector
Industry
CEO
Eli M. Wallace
Website
Headquarters
South San Francisco
Founded
2016
ISIN
US1079241022
FIGI
BBG01L3GYF02
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BBOT is 11.70 USD — it has decreased by −1.02% in the past 24 hours. Watch BridgeBio Oncology Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BridgeBio Oncology Therapeutics, Inc. stocks are traded under the ticker BBOT.
BBOT stock has risen by 9.04% compared to the previous week, the month change is a 23.17% rise, over the last year BridgeBio Oncology Therapeutics, Inc. has showed a 13.04% increase.
We've gathered analysts' opinions on BridgeBio Oncology Therapeutics, Inc. future price: according to them, BBOT price has a max estimate of 27.00 USD and a min estimate of 21.00 USD. Watch BBOT chart and read a more detailed BridgeBio Oncology Therapeutics, Inc. stock forecast: see what analysts think of BridgeBio Oncology Therapeutics, Inc. and suggest that you do with its stocks.
BBOT reached its all-time high on Aug 19, 2025 with the price of 12.50 USD, and its all-time low was 8.50 USD and was reached on Aug 5, 2025. View more price dynamics on BBOT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BBOT stock is 5.06% volatile and has beta coefficient of 0.08. Track BridgeBio Oncology Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is BridgeBio Oncology Therapeutics, Inc. there?
Yes, you can track BridgeBio Oncology Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
BridgeBio Oncology Therapeutics, Inc. is going to release the next earnings report on Dec 3, 2025. Keep track of upcoming events with our Earnings Calendar.
BBOT earnings for the last quarter are −49.62 USD per share, whereas the estimation was −42.45 USD resulting in a −16.88% surprise. The estimated earnings for the next quarter are −0.38 USD per share. See more details about BridgeBio Oncology Therapeutics, Inc. earnings.
BridgeBio Oncology Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BBOT net income for the last quarter is 918.31 K USD, while the quarter before that showed −487.39 K USD of net income which accounts for 288.41% change. Track more BridgeBio Oncology Therapeutics, Inc. financial stats to get the full picture.
No, BBOT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BBOT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BridgeBio Oncology Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BridgeBio Oncology Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BridgeBio Oncology Therapeutics, Inc. stock shows the strong buy signal. See more of BridgeBio Oncology Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.